United States

Securities and Exchange Commission

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended April 30, 2016

 

OR

 

[ ] TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934

 

From the transition period ___________ to ____________.

 

Commission File Number 333-152444

 

MEDCAREERS GROUP, INC .

(Exact name of small business issuer as specified in its charter)

 

Nevada 7389 26-1580812
(State or jurisdiction of incorporation or organization) 

(Primary Standard Industrial

Classification Code Number)

(IRS Employer

Identification No.) 

 

758 E Bethel School Road, Coppell, Texas 75019

(Address of principal executive offices)

 

(972) 393-5892

(Issuer's telephone number)

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Yes [X] No [ ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes [X] No [ ].

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large Accelerated Filer  [ ]   Accelerated Filer [ ]
 
Non-accelerated Filer  [ ]   Smaller Reporting Company [X]

 

 Indicate by a check mark whether the company is a shell company (as defined by Rule 12b-2 of the Exchange Act):

 

Yes [ ] No [X].

 

As of July 8, 2016 there were 571,577,017, shares of Common Stock of the issuer outstanding.

 

 

  1  
 

 

TABLE OF CONTENTS

 

 

     
PART I. FINANCIAL STATEMENTS (Unaudited) 3
     
ITEM 1. Financial Statements (Unaudited) 3
 

 

Notes to Financial Statements (Unaudited)

7
     
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 12

 

ITEM 3.

 

Quantitative and Qualitative Disclosure About Market Risk

18
     
ITEM 4. Controls and Procedures 19
     
     
PART II. OTHER INFORMATION 20
     
ITEM 1. Legal Proceedings 20
     
ITEM 1A. Risk Factors 20
     
ITEM 2. Unregistered Sales of Securities and Use of Proceeds 20
     
ITEM 3. Default Upon Senior Securities 25
     
ITEM 4. Mine Safety Disclosures 25
     
ITEM 5. Other Information 25
     
ITEM 6. Exhibits 25
     
     

 

 

  2  
 

 

MEDCAREERS GROUP, INC.

Consolidated Balance Sheets

April 30, 2016 and January 31, 2016

(Unaudited)

 

 

    April 30, 2016   Jan 31,  2016
Assets                
Current Assets                
  Cash and Cash Equivalents   $ 1,491     $ —    
  Accounts Receivable     995       995  
  Other Current Assets     —         83  
    Total Current Assets     2,486       1,078  
                 
                 
Total Assets   $ 2,486     $ 1,078  
                 
Liabilities and Stockholders’ Deficit                
Current Liabilities                
  Accounts Payable   $ 52,949     $ 48,226  
  Accrued Expenses     43,721       39,590  
  Accrued Interest Payable     317,711       290,682  
  Derivative Liabilities     983,147       745,129  
  Short Term Debt, net of Debt Discount of $147,731 and $104,900     822,471       799,572  
  Short Term Debt – Related Party, net of Debt Discount of $0 and $0     72,500       72,500  
    Total Current Liabilities     2,292,499       1,995,699  
                 
                 
   Total Liabilities     2,292,499       1,995,699  
                 
Stockholders’ Deficit                
Preferred Stock, $0.001 par value, 20,001,000 shares authorized,                
   330,000 and 0 shares issued and outstanding     330       330  
Common Stock, $0.001 par value, 4,000,000,000 shares authorized,                
   525,692,734 and 454,838,100 shares issued and outstanding     525,692       454,838  
                 
Additional Paid In Capital     5,581,706       5,582,991  
Accumulated Deficit
    (8,397,741 )     (8,032,780 )
Total Stockholders’ Deficit     (2,290,013 )     (1,994,621 )
                 
Total Liabilities and Stockholders’ Deficit   $ 2,486     $ 1,078  

 

 The Accompanying Notes are an Integral Part of these Unaudited Consolidated Financial Statements.

 

 

  3  
 

 

  

MEDCAREERS GROUP, INC.

Consolidated Statement of Operations

For the Three Months Ended April 30, 2016 and 2015

  (Unaudited)

 

 

         
    2016   2015
Revenue   $ 13,445     $ 22,435  
                 
Operating Expenses:                
   Cost of Revenues     1,000       2,345  
   Selling and Advertising Expenses     24,197       37,322  
   General and Administrative     78,182       72,036  
    Total Operating Expenses     103,379       111,703  
                 
Net Operating Loss     (89,934 )     (89,268 )
                 
Other Expense                
    Loss on Derivatives     (210,460 )     (191,846 )
    Loss on Debt Extinguishment     —         (45,359 )
    Interest Expense     (64,567 )     (90,726 )
    Total Other (Expense)     (275,027 )     (327,931 )
                 
Net Loss   $ (364,961 )   $ (417,199 )
                 
                 
Weighted Average Shares Outstanding     504,658,572       153,703,437  
Loss Per Share for Common Shareholders   $ (0.001 )   $ (0.003 )
                 

 

The Accompanying Notes are an Integral Part of these Unaudited Consolidated Financial Statements.

 

 

  4  
 

 

MEDCAREERS GROUP, INC.

Consolidated Statement of Changes in Stockholders’ Deficit

For the Three Months Ended April 30, 2016 (Unaudited)

 

                        Retained    
       Preferred Stock        Common Stock       Paid-In       Earnings          
      Shares       Amount       Shares       Amount       Capital       (Deficit)       Totals  
Stockholders' Deficit                                                        
   at January 31, 2016     330,000       330       454,838,100     $ 454,838     $ 5,582,991     $ (8,032,780 )   $ (1,994,621 )
                                                         
Conversion of                                                        
Notes Payable to Common
Stock 		                    70,854,634       70,854       (53,727 )             17,127  
Derivative Liability  Reclassification Due                                                        
    to Debt Conversion                                     52,442               52,442  
                                                         
Net Loss                                             (364,961 )     (364,961 )
                                                         
Stockholders' Deficit                                                        
at April 30, 2016     330,000       330       525,692,734     $ 525,692     $ 5,581,706     $ (8,397,741 )   $ (2,290,013 )

 

 

The Accompanying Notes are an Integral Part of these Unaudited Consolidated Financial Statements.

 

  5  
 

 

 

MEDCAREERS GROUP, INC.

Consolidated Statement of Cash Flows

For the Three Months Ended April 30, 2016 and 2015

(Unaudited)

  

 

    2016   2015
CASH FLOWS FROM OPERATING ACTIVITIES                
Net Loss   $ (364,961 )   $ (417,199 )
Adjustments to reconcile net loss to cash used by operating activities:                
  Loss on change of Derivative Liabilities     210,460       191,846  
  Loss of Debt Extinguishment     —         45,359  
  Amortization of Debt Discount     37,169       59,441  
  Amortization of Deferred Financing Costs     2,490       —    
                 
Change in Operating Assets and Liabilities:                
  Decrease (Increase) in Other Current Assets     83       —    
  Decrease (Increase) in Accounts Receivable     —         (5,000 )
  (Decrease) Increase in Accounts Payable     4,723       5,128  
  Increase in Accrued Expenses     4,131       8,816  
  Increase in Deferred Revenue     —         (3,000 )
  Increase in Interest Payable     27,396       28,787  
CASH FLOWS (USED IN) OPERATING ACTIVITIES     (78,509 )     (85,822 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES                
Proceeds from Notes Payable     80,000       65,500  
Payments on Notes Payable     —         (25,000 )
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES     80,000       40,500  
                 
NET INCREASE (DECREASE) IN CASH     1,491       (45,322 )
                 
CASH AT BEGINNING OF PERIOD     —         49,881  
                 
CASH AT END OF PERIOD   $ 1,491     $ 4,559  
                 
                 
Cash Paid for Interest   $ —       $ 12,721  
Income Taxes   $ —       $ —    
                 
Discount Related to Convertible Debt   $ 80,000     $ 54,179  
Issuance of Common Shares for Debt conversion   $ 17,127     $ 91,626  
APIC Write Off Due to Debt Conversion   $ 52,442     $ 258,534  
Debt Extinguished by Issuing New Debt   $ —       $ 97,920  

 

The Accompanying Notes are an Integral Part of these Unaudited Consolidated Financial Statements.

 

 

  6  
 

 

MEDCAREERS GROUP, INC.

Notes to Financial Statements

April 30, 2016 and 2015 (Unaudited)

 

 

NOTE 1 – NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Activities, History and Organization  – The Company was formed as RX Scripted, LLC on December 30, 2004 as a North Carolina limited liability company and converted to a Nevada corporation as RX Scripted, Inc. on December 5, 2007 and operates a website for nurses, nursing schools and nurses organizations which enables the respective entities to communicate more easily and efficiently with their members.

 

Significant Accounting Policies:

The Company’s management selects accounting principles generally accepted in the United States of America and adopts methods for their application.  The application of accounting principles requires the estimating, matching and timing of revenue and expense. The accounting policies used conform to generally accepted accounting principles which have been consistently applied in the preparation of these financial statements.

Basis of Presentation:

The Company prepares its financial statements on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States.

Use of Estimates:

In order to prepare financial statements in conformity with accounting principles generally accepted in the United States, management must make estimates, judgments and assumptions that affect the amounts reported in the financial statements and determine whether contingent assets and liabilities, if any, are disclosed in the financial statements. The ultimate resolution of issues requiring these estimates and assumptions could differ significantly from resolution currently anticipated by management and on which the financial statements are based.

Policy on Related Party Transactions:

 

The company has a formal, written policy that includes procedures intended to ensure compliance with the related party provisions in common practice for public companies. For purposes of the policy, a “related party transaction” is a transaction in which the Company or any one of its subsidiaries participates and in which a related party (including all of Medcareers’ directors and executive officers) has a direct or indirect material interest, other than ordinary course, arms-length transactions of less than 1% of the revenue of the counterparty. Any transaction exceeding the 1% threshold, and any transaction involving consulting, financial advisory, legal or accounting services that could impair a director’s independence, must be approved by the CEO. Any related party transaction in which an executive officer or a Director has a personal interest, or which could present a possible conflict under the Guide to Ethical Conduct, must be approved by Board of Directors, following appropriate disclosure of all material aspects of the transaction.

  

Recently Issued Accounting Pronouncements:

Revenue from Contracts with Customers:     In May 2014, ASC 606 was issued related to revenue from contracts with customers. Under this guidance, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The updated standard will replace most existing revenue recognition guidance under GAAP when it becomes effective and permits the use of either the retrospective or cumulative effect transition method. Early adoption is not permitted. The standard will be effective for the Company's fiscal year beginning January 1, 2017, including interim reporting periods within that year. The new guidance is not expected to have an impact on the Company's consolidated financial statements.

 

  7  
 

 

 

NOTE 2 - NOTES PAYABLE

 

The components of the Company’s debt as of April 30, 2016 and January 31, 2016 were as follows:

 

    Apr 2016   Jan 2016
Note Payable - $100,000, 12% interest payable monthly or accrued, due Nov 4, 2013   $ 100,000     $ 100,000  
Note Payable - $16,000, 12% interest added to note quarterly, due January 31, 2014     16,000       16,000  
Note Payable - $45,000, 12% interest added to note quarterly, due Nov 5, 2013     45,000       45,000  
Note Payable - $5,000, 12% interest added to note quarterly, due Nov 5, 2013     5,000       5,000  
Note Payable - $40,000, 12% interest added to note quarterly, due April 28, 2013     18,000       18,000  
Note Payable - $490,150, 12% interest payable monthly or accrued, due Oct 29, 2013     479,150       479,150  
Note Payable - $4,000, 12% interest added to note quarterly, due April 30, 2013     4,000       4,000  
Note Payable - $25,000, 12% interest added to note quarterly, due April 30, 2013     25,000       25,000  
Note Payable - $5,000, 12% interest added to note quarterly, due Nov 5, 2013     30,000       30,000  
Note Payable - $5,000, 8% interest payable accrued to maturity, due Nov 25, 2015     5,000       5,000  
Note Payable - $57,958, 8% interest payable accrued to maturity, due Sept 10, 2017     57,958       57,958  
Note Payable - $57,958, 8% interest payable accrued to maturity, due Sept 10, 2017     —         259  
Note Payable - $23,863, 8% interest payable accrued to maturity, due Sept 10, 2017     23,863       23,863  
Note Payable - $12,355 8% interest payable accrued to maturity, due Sept 10, 2017     12,355       12,355  
Note Payable - $34,280, 8% interest payable accrued to maturity, due Sept 10, 2017     10,950       27,450  
Note Payable - $38,677, 8% interest payable accrued to maturity, due Sept 10, 2017     38,677       38,677  
Note Payable - $25,000, 8% interest payable accrued to maturity, due Dec 7, 2017     25,000       25,000  
Note Payable - $25,000, 8% interest payable accrued to maturity, due Feb 3, 2018     25,000       —    
Note Payable - $30,000, 8% interest payable accrued to maturity, due March 3, 2018     30,000       —    
Note Payable - $25,000, 8% interest payable accrued to maturity, due March 24, 2018     25,000       —    
Deferred Financing Costs     (5,751 )     (8,240 )
Debt Discount     (147,731 )     (104,900 )
Subtotal   $ 822,471     $ 799,572  
Related Party Debt                
Note Payable - $19,500, 8% interest payable accrued until maturity, due Jan 2, 2015                
Note Payable - $5,500, 8% interest payable accrued until maturity, due July 8, 2015     5,500       5,500  
Note Payable - $4,500, 8% interest payable accrued to maturity, due May 5, 2015     4,500       4,500  
Note Payable - $24,297, 8% interest payable accrued to maturity, due May 14, 2015     23,297       23,297  
Note Payable - $7,703, 8% interest payable accrued to maturity, due May 19, 2015     7,703       7,703  
Note Payable - $26,500, 8% interest payable accrued to maturity, due June 12, 2015     26,500       26,500  
Note Payable - $5,000, 8% interest payable accrued until maturity, due July 19, 2016     5,000       5,000  
Subtotal – Related Party Debt     72,500       72,500  
Total   $ 894,971     $ 872,072  
                 

 

The Company had accrued interest payable of $317,711 and $290,682 interest on the notes at April 30, 2016 and January 31, 2016, respectively.

 

  8  
 

 

 

The Company has entered in to various promissory notes with lenders during the three months ended April 30, 2016 and the year ended January 31, 2016 bearing interest at between 8% and 12% rate per annum, unsecured, payable on demand and convertible into the Company’s common stock. The conversion price ranges from 52% to 50% of the average of the three lowest closing bid prices of the common stock during the 10 or 25 trading days prior to conversion.

 

The Company analyzed the conversion option for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the instrument should be classified as liabilities due to there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The instrument is measured at fair value at the end of each reporting period or termination of the instrument with the change in fair value recorded to earnings. 

During the three months ended April 30, 2016, the Company converted a total of $17,127 of the convertible debt plus accrued interest into 70,854,634 common shares.

 

A summary of the debt in total is as follows:

 

    2016   2015
Convertible debt – fixed conversion rate   $ 692,150     $ 692,150  
Convertible debt – variable conversion rates, net of debt discount     105,321       82,422  
Convertible debt – variable conversion rates, Related Party, net of debt discount     72,500       72,500  
Non-Convertible debt     25,000       25,000  
Net   $ 894,971       872,072  

 

 

The Company has $692,150 and $692,150 of debt that is convertible at ranges from $0.06 to $1.00 per share and accrues interest between 8% and 12% at April 30,2016 and January 31, 2016 respectively.

 

The Company has $25,000 and $25,000 of debt which has no conversion feature at April 30, 2016 and January 31, 2016 respectively.

 

The Company has $105,321 and $82,422 of debt (net of debt discount) with variable conversion price ranges from 52% to 50% of the average of the three lowest closing bid prices of the common stock during the 10 or 25 trading days prior to conversion as of April 30, 2016 and January 31, 2016 respectively.

 

The company has $72,500 of related party convertible debt at April 30, 2016 and January 31. 2016.

 

 

The Company is in default on a number of its promissory notes which provide legal remedies for satisfaction of defaults, none of which to this point have pursued their legal remedies. The Company continues to accrue interest at the listed rates, and plans to seek their conversion or payoff within the next twelve months. Accordingly, the Company has classified the entire loan amounts as a current liability.

 

 

NOTE 3 - STOCKHOLDERS’ DEFICIT

Preferred Stock:

The Company is authorized to issue 20,001,000 shares of Preferred Stock, having a par value of $0.001 per share, of which 500,000 are designated as Series A and 1,000 are designated as Series B. 

There were 330,000 Series A preferred shares outstanding at April 30, 2016 and January 31, 2016.

There were 1,000 Series B preferred shares outstanding at April 30, 2016 and January 31, 2016.

 

  9  
 

 

Common Stock:

The Company is authorized to issue 4,000,000,000 common shares at a par value of $0.001 per share.  These shares have full voting rights.  At April 30, 2016 and January 31, 2016, there were 525,692,734 and 454,838,100 shares outstanding, respectively.  No dividends were paid in the period ended April 30, 2016 or in the year ended January 31, 2016.  

The Company issued the following shares of common stock in the year ended April 30, 2016:      
Conversion of Notes Payable to Common Stock     70,854,634
The company issued 70,854,634 shares of common stock for the conversion of Notes payable and accrued interest in the amount of $17,127.      
       

Options and Warrants:

The Company recorded option and warrant expense of $0 in the period ended April 30, 2016 and the year ended January 31, 2016.

 

The Company had the following options or warrants outstanding at April 30, 2016:

 

Issued To # Options Dated Expire Strike Price  
Shareholder 127,500 08/28/2011 08/28/2016 $0.10 per share  
Shareholder 127,500 04/29/2012 04/29/2017 $0.10 per share  
Shareholder 127,500 07/31/2013 07/31/2017 $0.10 per share  
Shareholder 1,000,000 08/31/2012 08/31/2016 $0.12 per share  
Shareholder 2,000,000 01/18/2013 01/18/2018 $0.05 per share  
Lender 3,500,000 07/02/2015 07/01/2019 $0.10 per share  
           
           
      Options     Weighted Average     Warrants   Weighted Average
  Exercise Exercise
  Price Price
  Outstanding at January 31, 2016     -     $   0.25       6,982,500   $ 0.09
  Granted     -                        
  Exercised     -         —       —     —
  Forfeited and canceled     -                 100,000       
  Outstanding at April 30, 2016     -     $   —       6,882,500   $ 0.13
           
           
           
                         
  Summary of warrants outstanding and exercisable as of April 30, 2016 is as follows:        
                         
  Range of Exercise   Weighted  Average       Number of  Warrants Number of Warrants  
  Prices Remaining Contractual     Outstanding Exercisable  
    Life (years)          
  $ 0.05 to $ 0.12     1.86       6,882,500     6,882,500  
                      0  
  $ 0.05 to $ 0.12     1.86       6,882,500     6,882,500  
                         
                                                                 

 

 

  10  
 

 

 

NOTE 4 – COMMITMENTS AND CONTINGENCIES

 

There is pending litigation initiated by the Company around the validity of a $100,000 note which the Company signed based upon representations of funding from the maker which were never received. The Company is initiated litigation to dispute the note and the 10,151, 540 shares that have been issued.

 

 

NOTE 5 - GOING CONCERN AND FINANCIAL POSITION

 

MedCareers’ financial statements are prepared using United States generally accepted accounting principles applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  The Company has incurred cumulative losses through April 30, 2016 of $8,397,741 and has a working capital deficit at April 30, 2016 of $(2,290,013).

 

Historically, revenues have not been sufficient to cover operating costs that would permit the Company to continue as a going concern.  The potential proceeds from the sale of common stock and other contemplated debt and equity financing, and increases in operating revenues from new development and business acquisitions might enable MedCareers to continue as a going concern.  These conditions raise substantial doubt about the company’s ability to continue as a going concern. There can be no assurance that the Company can or will be able to complete any debt or equity financing, or develop or acquire one or more business interests on terms favorable to it.  MedCareers’ financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

NOTE 6 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The ASC guidance for fair value measurements and disclosure establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).  The three levels of the fair value hierarchy are described below:

Level 1 Inputs – Quoted prices for identical instruments in active markets.

Level 2 Inputs – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 Inputs – Instruments with primarily unobservable value drivers.

As of April 30, 2016 and January 31, 2016, the Company’s financial assets were measured at fair value using Level 3 inputs, with the exception of cash, which was valued using Level 1 inputs.

 

  11  
 

Fair Value Measurement at April 30, 2016 Using:

   

 

 

 

 

 

April 30, 2016

  Quoted Prices in Active
Markets
For Identical Assets
(Level 1) 		 

 

Significant Other
Observable
Inputs
(Level 2)

 

 

 

Significant
Unobservable
Inputs
(Level 3)

                 
Assets:                
None   $                —   $                 —   $               —   $                 —
Totals   $                 —    $                 —   $               —   $                 —
                 
Liabilities:                
   Derivative Liabilities   $ 983,147     $ —       $ —       $ 983,147  
      Totals   $ 983,147     $ —       $ —       $ 983,147  
                                 
     

 

 

 

 

 

January 31, 2016

      Quoted Prices in Active
Markets
For Identical Assets
(Level 1) 		     

 

Significant Other
Observable
Inputs
(Level 2)

     

 

 

Significant
Unobservable
Inputs
(Level 3)

 
Assets:                                
None     —         —         —         —    
  Totals   $ —       $ —       $ —       $ —    
                                 
                                 
Liabilities:                                
   Derivative Liabilities   $ 745,129       —         —         745,129  
      Totals   $ 745,129     $ —       $ —       $ 745,129  
                                 

 

Derivative Liability:

As of April 30, 2016 and January 31, 2016 the company had $983,147 and $745,129 recorded as derivative liabilities. During the periods ended April 30, 2016 and January 31, 2016 the company recorded $210,460 in loss and $633,185 in loss from the change in the fair value of derivative liabilities.

The derivative liabilities are valued as a level 3 input for valuing financial instruments.

The derivatives arise from convertible debt where the debt is convertible into common stock at variable conversion prices. As the price of the common stock varies it triggers a gain or loss based upon the discount to market assuming the debt was converted at the balance sheet date.

 

  12  
 

 

The fair value of the derivative liability is determined using the Black-Scholes option-pricing model, is re-measured on the Company’s reporting dates, and is affected by changes in inputs to that model including our stock price, expected stock price volatility, the expected term, and the risk-free interest rate. In our calculation at April 30, 2016, volatility ranged from 385% to 437%, the term ranged from 0.49 to 0.64 years, and the risk free interest rate was 6%.

 

  Level 3
  Derivatives
Balance, January 31, 2016 $ 745,129  
Derivative Liabilities due to New Convertible Debt $ 210,460  
   Reclassification of Derivative Liabilities to Additional Paid in Capital       
     Due to Conversion of Notes Payable  $ (52,442 )
   Market to Market adjustment of Derivatives $  80,000  
Ending Balance, April 30, 2016 $ 983,147  
       

 

 

NOTE 7 – RELATED PARTY TRANSACTIONS

 

The Company maintains its executive offices of approximately 300 sq. ft., at 758 E. Bethel School Road, Coppell, Texas 75019 in the home of the President and CEO for which it pays no rent. The Company plans to lease office space when their operations require it and funding permits.

 

NOTE 8 - SUBSEQUENT EVENTS

 

Subsequent to April 30, 2016, the Company borrowed $25,000 on a Convertible Notes:

 

Note Payable: $4,000.00 Unruh note plus interest was assigned to Blackbridge Capital Growth Fund, LLC

 

Note Payable - $25,000, 9% interest payable accrued until maturity, due Feb 5, 2017 $25,000

 

In the period since April 30, 2016, the Company issued 35,962,743 shares of restricted common stock pursuant to the conversion of $6,293.48 of the Unruh convertible promissory note and interest. The Notes provided conversion features which was tied to the market price of the Company’s common stock.

 

 

  13  
 

 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, which we refer to in this quarterly report as the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to in this quarterly report as the Exchange Act. Forward-looking statements are not statements of historical fact but rather reflect our current expectations, estimates and predictions about future results and events. These statements may use words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “predict,” “project” and similar expressions as they relate to us or our management. When we make forward-looking statements, we are basing them on our management’s beliefs and assumptions, using information currently available to us. These forward-looking statements are subject to risks, uncertainties and assumptions, including but not limited to, risks, uncertainties and assumptions discussed in this quarterly report. Factors that can cause or contribute to these differences include those described under the headings “Risk Factors” and “Management Discussion and Analysis and Plan of Operation.”

If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we projected. Any forward-looking statement you read in this quarterly report reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. All subsequent written and oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by this paragraph. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this quarterly report. The Company expressly disclaims any obligation to release publicly any updates or revisions to these forward-looking statements to reflect any change in its views or expectations. The Company can give no assurances that such forward-looking statements will prove to be correct.

 

Company

MedCareers Group, Inc. (“ MedCareers ”, the “ Company ”, “ we ” or “ us ”), the Company described herein, is a Nevada corporation, with offices located at 758 E. Bethel School Road, Coppell, Texas 75019. It can be reached by phone at (972) 393-5892.

 

Recent Activity

 

At the end of our fiscal year end and through our first quarter of FY 2017 we have concentrated our efforts into re-launching the employer area of our network into a talent acquisition platform for hiring nurses.

  

One of the goals is to have upward of 10,000 paid nursing jobs posted on our job board from healthcare systems across the country. By achieving this goal we will be one of the largest nursing job sites for direct hire employers such as hospitals as opposed to travel firms. As of April 30, 2016 we had reached 25% of our goal with 2,500 jobs posted or under contract to be posted. We believe the 10,000 jobs will be achieved with between 60 and 100 health systems under contract.

 

Management is still looking to add approximately 5 commission business partners to represent us in 5 of our 7 regions. These representatives will be responsible for revenue generation and membership growth in their assigned markets.

 

Additionally we have had some unsolicited sales from organizations wanting to purchase targeted email campaigns since year-end. The sales ranged between $1,000 and $2,500. We believe as our membership grows there will be a tremendous sales opportunity for these transactions. As we do not sale our member lists, this transactions consist of our sending a clients email to a targeted group of nurses defined by the client through our own email service.

 

Our financial statements contain information expressing substantial doubt about our ability to continue as a going concern. The consolidated financial statements have been prepared " assuming that we will continue as a going concern, " which contemplates that we satisfy our liabilities and commitments in the ordinary course of business.

 

  14  
 

 

Competition

 

While there are various online community forums and nurse portals, Nurses Lounge does not believe that there is a direct competitor designed from the ground up as a professional network for nurses and to solve many of the day-to-day communications problems nursing organizations have.  The largest competitors of Nurses Lounge bill themselves as “ communities ” that claim to provide news, career advice and social interaction, and include Nurse.com - owned by OnCourse Learning; and Allnurses – a nursing forum and discussion board.  Additionally, and to a lesser extent, Nurses Lounge indirectly competes with other websites that encourage users to create connections with other colleagues and persons with similar interests such as Linkedin and Facebook, however, unlike like these websites which have very broad general appeal, Nurses Lounge focuses solely on the nursing pro and the organizations which support them.

 

Proprietary Rights

 

We plan to rely on a combination of copyright, trade secret and trademark laws, and non-disclosure and other contractual arrangements to protect our proprietary rights moving forward. There can be no assurance that the steps we plan to take in the future to protect our future proprietary rights, however, will be adequate to deter misappropriation of proprietary information, and we may not be able to detect unauthorized use and take appropriate steps to enforce our intellectual property rights. Although we believe that our websites and services will not infringe upon the intellectual property rights of others and that we have all rights necessary to utilize our intellectual property, we are subject to the risk of claims alleging infringement of third-party intellectual property rights. Any such claims could require us to spend significant sums on litigation, pay damages, delay our products and software, develop non-infringing intellectual property or acquire licenses to intellectual property that are the subject of any such infringement. Therefore, such claims could have a material adverse effect on our planned business, operating results and financial condition.

 

Nursing Profession Overview

 

From Nurses Lounge business viewpoint, the nursing profession is broken down into the individual registered nurses (RNs) and the professions stake holder organizations consisting of nursing schools, associations and employers.

 

Throughout their career, nurses need to be connected with numerous organizations in order to simply stay up to date with basic continuing education requirements which they need to meet state guidelines and/or employers qualification to maintain employment.

As such, we believe that there is an opportunity to unite the industry on one simple to use communication platform that can upgrade, simplify and reduce the cost of communications used by stakeholder organizations while providing nurses quick access to the information important to their careers. The market for nurses is growing in the United States and we believe that our website has a significant number of potential users based on the following:

  • According to the Bureau of Labor Statistics’ Employment Projections 2010-2020 released in February 2012, the Registered Nursing workforce is the top occupation in terms of job growth through 2020. It is expected that the number of employed nurses will grow from 2.74 million in 2010 to 3.45 million in 2020, an increase of 712,000 or 26%.
    •  

  • Based on findings from the Nursing Management Aging Workforce Survey released in the July 2006 issue of Nursing Management magazine, 55% of surveyed nurses reported their intention to retire between 2011 and 2020.

  • Approximately 660 4-year schools offer a Bachelor of Science in Nursing (BSN) and other advanced degrees such as Masters and PhD.

  • Approximately 2,500 community college type schools offer a 2 year Associate Degree in Nursing (ADN).

  • Approximately 6,000 hospitals are located across the U.S. where approximately 60% of all nurses are employed, according to American Association Colleges of Nursing (AACN).

  • An approximate 250,000 shortage in nurses has been predicted by 2018.

 

  15  
 

 

 

Due to the above factors, the Company’s Nurses Lounge professional Network has a significant market for their services and that even with significant competition for recruitment and job placement services as described below in the risk factor entitled “ WE WILL FACE SIGNIFICANT COMPETITION FROM MONSTER.COM and CAREERBUILDER, NICHE HEALTHCARE SITES SUCH AS NURSE.COM AND HEALTHECAREERS AS WELL AS JOB AGGREGATOR SITES SUCH AS INDEED.COM AND OTHER INTERNET JOB POSTING WEBSITES”. ”, there will be room in the global marketplace for website posting, recruiting and job placement services for the Company’s niche healthcare related websites.

 

***

 

Results for the three months ended April 30, 2016

Revenue for the three months ended April 30, 2016 and 2015 was $13,445 and $22,435, respectively. The lower revenue for the first quarter in 2016 was primarily due to sales to staffing firms at a price of $6,000 in 2015 versus an average sales price to healthcare systems at rate of approximately $995.00. As a result the total number of sales in 1 st quarter of 2016 is greater than in same period the previous year.

Cost of revenues were $1,000 and $2,345 for the three months ended April 30, 2016 and 2015, respectively. The changes reflect the swings in costs as the Company promotes its nurse portal and the variation in those costs as the Company has yet to enter a period where the operations in sales and cost of sales are relatively constant. Until the Company enters a reasonably constant operating period, the costs will vary widely.

Selling expenses were $24,197 and $37,322 for the three months ended April 30, 2016 and 2015. This decrease was due to the President doing more of the sales presentations rather than paying rather than paying others to do this work.

Operating expenses for the three months ended April 30, 2016 and 2015 were $103,379 and $72,036 respectively.

Other expense reflects interest on loans which was $64,567 and $90,726 expense for the three months ended April 30, 2016 and 2015, respectively. Also, there were other expenses relating to the cost of our convertible debt being a loss on derivatives of $210,460 and $191,846 for the three months ended April 30, 2016 and 2015 respectively. We also incurred a loss on debt extinguishment for the three months ended April 30, 2016 and 2015 of $0 and $45,359 respectively.

Liquidity and Capital Resources

As of April 30, 2016, the Company had negative working capital of $2,290,013, comprised of current assets of $2,486 and current liabilities of $2,292,499.

 

Net cash used in operations for the three months ended April 30, 2016 was $78,509 compared to $85,822 for the three months ended April 30, 2015.

 

Cash used for purchase of fixed assets was $0 for the three months ended April 30, 2016 and 2015.

 

Cash provided by financing activities for the three months ended April 30, 2016 was $80,000 compared to $40,500 for the same period in 2015.

 

The Company has borrowed funds and/or sold stock for working capital.  These transactions are detailed in the section “Recent Sales of Unregistered Securities”.

 

 

  16  
 

 

 

Currently the Company does not have sufficient cash reserves or revenues to meet its contractual obligations under its outstanding notes payable and to pay its ongoing monthly expenses, which the Company anticipates totaling approximately $300,000 over the next 12 months.  The Company has been able to continue operating to date largely from loans made by its shareholders and other debt financings to date.  The Company is currently looking at both short-term and more permanent financing opportunities, including debt or equity funding, bridge or short term loans, and/or traditional bank funding, but we have not decided on any specific path moving forward.  Unless we have raised sufficient funding to pay our ongoing expenses associated with being a public company, and we have sufficient funds to support our planned operations, the Company can provide no assurances that it will be able to meet its short and long term liquidity needs. The Company continues to generate revenue from the Nurses Lounge business, which the Company believes will increase to the point where the Company can cover its basis monthly obligations, of which there can be no assurance.

Our financial statements contain information expressing substantial doubt about our ability to continue as a going concern. The consolidated financial statements have been prepared " assuming that we will continue as a going concern, " which contemplates that we satisfy our liabilities and commitments in the ordinary course of business.

 

We do not currently have any additional formal commitments or identified sources of additional capital from third parties or from our officers, director or significant shareholders. We can provide no assurance that additional financing will be available on favorable terms, if at all. If we are not able to raise the capital necessary to continue our business operations, we may be forced to abandon or curtail our business plan.

 

In the future, we may be required to seek additional capital by selling additional debt or equity securities, selling assets, if any, or otherwise be required to bring cash flows in balance when we approach a condition of cash insufficiency. The sale of additional equity or debt securities, if accomplished, may result in dilution to our then shareholders. We provide no assurance that financing will be available in amounts or on terms acceptable to us, or at all.

 

 

ITEM 3. Quantitative and Qualitative Disclosure about Market Risk.

 

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), we are not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

 

ITEM 4. Controls and Procedures

(a)           Evaluation of disclosure controls and procedures. Our Chief Executive Officer and Principal Financial Officer, after evaluating the effectiveness of our " disclosure controls and procedures " (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q (the " Evaluation Date "), has concluded that as of the Evaluation Date, our disclosure controls and procedures were not effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.  Moving forward, we hope that our Chief Executive Officer and Principal Financial Officer will be able to devote the additional time and effort required so that our disclosure controls and procedures are once again effective.  Notwithstanding the assessment that our internal controls and procedures were not effective, we believe that our financial statements contained in this Quarterly Report for the quarter ended October 31, 2015 fairly present our financial position, results of operations and cash flows for the years and months covered thereby in all material respects.

 

(b)          Changes in internal control over financial reporting. There were no changes in our internal control over financial reporting during our most recent fiscal quarter that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.

 

 

  17  
 

 

PART II

 

Item 1. Legal Proceedings

 

There is pending litigation initiated by the Company around the validity of a $100,000 note which the Company signed based upon representations of funding from the maker which were never received. The Company is initiated litigation to dispute the note and the 10,151, 540 shares that have been issued.

 

Item 1A. Risk Factors

 

There have been no material changes from the risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the year ended January 31, 2016, filed with the Commission on June 27, 2016, other than as set forth below, and investors are encouraged to review such risk factors below and in the Form 10-K, prior to making an investment in the Company.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Recent Sales of Unregistered Securities

 

  Consideration   Date # Shares
Balance, Number of shares outstanding, January 31, 2016      

454,838,100

Common stock at issued fifty percent discount to market per note conversion agreement Convert a portion of note payable (1) Feb 5, 2016

 

27,525,867

Common stock at issued fifty percent discount to market per note conversion agreement Convert a portion of note payable (2) Mar 11, 2016

 

43,328,767

Balance, Number of shares outstanding, April 30, 2016       525,692,734

 

 

(1) Partial conversion of Note that had a conversion feature at 50% of market price per share. These shares were issued for the conversion of $4,129 of the note plus accrued interest.

The Company claims an exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Act”) since the foregoing issuances and grants did not involve a public offering, the recipients took the shares and options for investment and not resale, the Company took appropriate measures to restrict transfer, and the recipients were either (a) “accredited investors” and/or (b) had access to similar documentation and information as would be required in a Registration Statement under the Act. No underwriters or agents were involved in the foregoing issuances and the Company paid no underwriting discounts or commissions.

 

(2) Partial conversion of Note that had a conversion feature at 50% of market price per share. These shares were issued for the conversion of $12,998 of the note and accrued interest.

The Company claims an exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Act”) since the foregoing issuances and grants did not involve a public offering, the recipients took the shares and options for investment and not resale, the Company took appropriate measures to restrict transfer, and the recipients were either (a) “accredited investors” and/or (b) had access to similar documentation and information as would be required in a Registration Statement under the Act. No underwriters or agents were involved in the foregoing issuances and the Company paid no underwriting discounts or commissions.

 

Options and Warrants

 

The Company had the following options or warrants outstanding at April 30, 2016:

 

Issued To # Options Dated Expire Strike Price
Shareholder (1) 127,500 04/29/2012 04/29/2017 $0.10 per share
Shareholder (1) 127,500 08/28/2011 08/28/2016 $0.10 per share
Shareholder (1) 127,500 07/31/2013 07/31/2017 $0.10 per share
Shareholder (2) 1,000,000 08/31/2012 08/31/2016 $0.12 per share
Shareholder (4) 2,000,000 01/18/2013 01/18/2018 $0.05 per share
Lender (5) 3,500,000 07/02/2014 07/01/2019 $0.10 per share

 

  18  
 

 

 

(1) Three options for 127,500 shares of restricted common stock at an exercise price of $0.10 per share and for a term of 5 years was awarded Gen eva7, LLC in consideration for renewing the loan it has with the company of $25,000 two times. Geneva7, LLC originally loaned the company $25,000 at 12% interest on August 29, 2011 and was awarded an option to purchase 127,500 shares of restricted common stock at an exercise price of $0.10. The term of the option is 5 years and expired without it being exercised. The loan matured on April 30 th 2012 and Geneva 7 agreed to renew the loan and accrue interest thru July 31, 2013 and additionally renewed the loan thru October 31, 2103 when it matured on July 31, 2013. With each additional renewal Geneva7 received an additional option to purchase 127,500 shares of restricted common stock at an exercise price of $0.10 per share and for a term of 5 years. This note was sold to a third party who converted the note into common shares at market and sold the shares.

 

(2) Warrant 1,000,000 shares. The Company entered into a contract for services with Horse and Hammerhead Marketing Solutions, LLC , a management consulting firm. Based on the agreement, the consultant was issued a warrant for 1,000,000 shares of MCGI’s restricted common stock at an exercise price of $0.12 per/share with a 4-year term.

The Company claims an exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Act”) since the foregoing issuances and grants did not involve a public offering, the recipients took the shares and options for investment and not resale, the Company took appropriate measures to restrict transfer, and the recipients were either (a) “accredited investors” and/or (b) had access to similar documentation and information as would be required in a Registration Statement under the Act. No underwriters or agents were involved in the foregoing issuances and the Company paid no underwriting discounts or commissions.

 

(4) On January 9, 2013 the company issued 2,000,000 units of its securities in a private placement to an accredited investor. The price of these Units was $0.10 per unit. Each Unit consists of 1 share of restricted common stock valued at $0.10 per share for a total of 2,000,000 shares and one 5 year Warrant. Each Series B Warrant entitles the holder to purchase one share of common stock at an exercise price of $0.05 per share and subject to adjustments due to recapitalization or reclassification of common stock.

The Company claims an exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Act”) since the foregoing issuances and grants did not involve a public offering, the recipients took the shares and options for investment and not resale, the Company took appropriate measures to restrict transfer, and the recipients were either (a) “accredited investors” and/or (b) had access to similar documentation and information as would be required in a Registration Statement under the Act. No underwriters or agents were involved in the foregoing issuances and the Company paid no underwriting discounts or commissions.

 

(5) Option for 3,500,000 common shares granted to a lender as part of the loan transaction. The options have a strike price of $0.10 per share and expire on July 1, 2019.

The Company claims an exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Act”) since the foregoing issuances and grants did not involve a public offering, the recipients took the shares and options for investment and not resale, the Company took appropriate measures to restrict transfer, and the recipients were either (a) “accredited investors” and/or (b) had access to similar documentation and information as would be required in a Registration Statement under the Act. No underwriters or agents were involved in the foregoing issuances and the Company paid no underwriting discounts or commissions.

 

 

 

  19  
 

 

 

Item 3. Default Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

See the Exhibit Index immediately following the signature page of this Report on Form 10-Q.

 

  20  
 

 

SIGNATURES

 

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Medcareers Group, Inc.

 

By:   /s/ Timothy Armes

Timothy Armes

Chairman (Director), Chief Executive Officer, President, Secretary and Treasurer

 

Date: July 8, 2016

 

 

 

 

 

 

 

 

 

  21  
 

 

EXHIBIT INDEX

 

Exhibit

Number

Description of Exhibit
   
   
31.1* Certificate of the Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
32.1* Certificate of the Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   

 

*   Filed herewith.

 

 

 

 

 

 

  22